Deruxtecan - Wikipedia
WEBDeruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor. [1] It is available linked to specific monoclonal antibody (antibody–drug conjugate), such as: Trastuzumab deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. [2]
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WEBJul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2-targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.
Trastuzumab deruxtecan in HER2-positive advanced breast …
WEBSep 13, 2024 · Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced ...
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic …
WEBTrastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. Methods: We conducted a phase 3, multicenter, open-label trial involving patients with hormone receptor-positive metastatic breast cancer with low …
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell …
WEBSep 18, 2021 · Trastuzumab deruxtecan (formerly DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for …
WEBMar 23, 2022 · Trastuzumab deruxtecan (also known as T-DXd and DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload...
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With …
WEBOct 23, 2023 · Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors.
Datopotamab–deruxtecan in early-stage breast cancer: the
WEBSep 14, 2024 · Here, we report the safety and efficacy results of the evaluation of datopotamab–deruxtecan (Dato-DXd), an arm in block A of I-SPY2.2. Dato-DXd is an antibody drug conjugate (ADC) comprising a ...